Metabolic Dysfunction–Associated Steatotic Liver Disease, Alcohol Consumption, and the Risk of Atrial Fibrillation: A Nationwide Population‐Based Study
Open Access
- 15 July 2025
- journal article
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 14 (14) , e042003
Abstract
Background: The recent reclassification of steatotic liver disease into metabolic dysfunction–associated steatotic liver disease (MASLD) and metabolic dysfunction‐associated alcohol‐related liver disease has highlighted their potential cardiovascular implications. This study aimed to investigate the impact of MASLD and metabolic dysfunction‐associated alcohol‐related liver disease on the risk of newly diagnosed atrial fibrillation (AF). Methods: Data from 362 285 participants who underwent a health screening in 2009 to 2010, sourced from the Korean National Health Insurance database, were identified, and we retrospectively analyzed their data through 2019. Excluding those with other liver diseases and heavy alcoholics, 206 455 participants with a fatty liver index were included. The primary outcome was newly diagnosed AF; associated conditions, such as ischemic stroke and heart failure, were also investigated. Participants were classified into 4 groups based on their steatotic liver disease status and alcohol consumption levels. Results: Over a median follow‐up of 9.6 years, 5335 participants were newly diagnosed with AF (2.74 per 1000 person‐years). The risk of AF was significantly higher in patients with MASLD who did not consume alcohol (adjusted hazard ratio [aHR], 1.32 [95% CI, 1.23–1.41]; P P P =0.011). Conclusions: MASLD is associated with incident AF. These findings suggest that metabolic dysfunction plays a more significant role in AF occurrence than the direct toxic effects of alcohol.Keywords
This publication has 32 references indexed in Scilit:
- Metabolic dysfunction-associated steatotic liver disease increases the risk of incident cardiovascular disease: a nationwide cohort studyeClinicalMedicine, 2023
- Impact of Nonalcoholic Fatty Liver Disease on Arrhythmia Recurrence Following Atrial Fibrillation AblationJACC: Clinical Electrophysiology, 2020
- The degree of hepatic steatosis associates with impaired cardiac and autonomic functionJournal of Hepatology, 2019
- Edoxaban in Asian Patients With Atrial FibrillationJACC, 2018
- Lifetime Risks, Projected Numbers, and Adverse Outcomes in Asian Patients With Atrial FibrillationChest, 2018
- Nonalcoholic Steatohepatitis is Associated with Cardiac Remodeling and DysfunctionObesity, 2017
- Metabolic syndrome, atrial fibrillation, and stroke: Tackling an emerging epidemicHeart Rhythm, 2015
- Alcohol Consumption and Risk of Atrial FibrillationJACC, 2014
- Hepatic steatosis index: A simple screening tool reflecting nonalcoholic fatty liver diseaseDigestive and Liver Disease, 2010
- Design and validation of a histological scoring system for nonalcoholic fatty liver disease†Hepatology, 2005